Early predictive factors in routine clinical practice for rituximab therapy response in patients with rheumatoid arthritis

Introduction Identifying early predictive factors of how rheumatoid arthritis (RA) patients respond to rituximab (RTX) treatment is crucial for both individual treatment outcome and the improvement of clinical practice overall. This study aimed to identify early predictive factors available in stand...

Full description

Bibliographic Details
Published in:	Rheumatology
Main Authors:	Evgenija Mihajloska, Aleksandar Dimkovski, Aleksandra Grozdanova, Ana Vasilevska, Dubravka Antova, Zorica Naumovska, Aleksandra Kapedanovska Nestorovska, Zoran Sterjev, Bashkim Osmani, Ljubica Shuturkova
Format:	Article
Language:	English
Published:	Termedia Publishing House 2024-06-01
Subjects:	rituximab predictive factors predictive model rheumatoid arthritis
Online Access:	https://reu.termedia.pl/Early-predictive-factors-in-routine-clinical-practice-for-rituximab-therapy-response,189780,0,2.html

Similar Items

Evaluation of inflammatory markers in patients with confirmed bacterial infection according to the type of isolated pathogen
by: Jelena Micik, et al.
Published: (2025-12-01)

Toward value in healthcare: opportunities and challenges for implementing Value-Based Healthcare in North Macedonia
by: Aleksandra Grozdanova, et al.
Published: (2025-10-01)

Role of the hospital pharmacists during COVID-19 pandemic in the RN Macedonia
by: Zorica Naumovska, et al.
Published: (2024-12-01)

Assessment of Patient Satisfaction with Pharmaceutical Community Services in R. Macedonia
by: Zoran Sterjev, et al.
Published: (2011-06-01)

AKR1D1*36 C>T (rs1872930) allelic variant is associated with variability of the CYP2C9 genotype predicted pharmacokinetics of ibuprofen enantiomers – a pilot study in healthy volunteers
by: Kapedanovska Nestorovska Aleksandra, et al.
Published: (2019-09-01)

Challenges to patients’ rights during the COVID-19 pandemic: survey of public perceptions in North Macedonia
by: Katerina Kuzmanova, et al.
Published: (2024-12-01)

Comparison of the efficacy and safety of the original rituximab and its biosimilar in routine clinical practice
by: D. A. Kusevich, et al.
Published: (2022-06-01)

Cost-Effectiveness of Oral Nutritional Supplements in Malnourished or at Risk of Disease-Related Malnutrition Cancer Patients in North Macedonia
by: Kapedanovska Nestorovska A, et al.
Published: (2025-03-01)

Recent advances in isatin-derived hybrids: promising multifunctional agents for drug development
by: Aleksandar Dimkovski, et al.
Published: (2025-12-01)

Synthesis, Biological Evaluation, and Molecular Docking Studies of Novel Coumarin–Triazole–Isatin Hybrids as Selective Butyrylcholinesterase Inhibitors
by: Aleksandar Dimkovski, et al.
Published: (2025-05-01)

USE OF RITUXIMAB IN PATIENTS WITH LUPUS NEPHRITIS
by: Anna Vasilyevna Torgashina, et al.
Published: (2010-08-01)

EXPERIENCE WITH RITUXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS
by: Mikhail Sergeyevich Protopopov, et al.
Published: (2013-02-01)

Use of rituximab in systemic lupus erythematosus in children: a review
by: A. N. Arefyeva
Published: (2019-11-01)

Rituximab in Autoimmune CNS Disease
by: J Gordon Millichap, et al.
Published: (2014-08-01)

Lupus Nephritis, the therapy and the role of Rituximab in resistant cases
by: Hussein A. Nasir, et al.
Published: (2014-01-01)

The Use of Rituximab in Glomerulonephritis: What Is the Evidence?
by: Wenjuan Zhu, et al.
Published: (2025-09-01)

Rituximab in Kidney-Limited Microscopic Polyangiitis
by: Anvitha Madhavaram, et al.
Published: (2023-12-01)

Acquired angioedema and rituximab-induced acute thrombocytopenia in splenic marginal zone lymphoma
by: Odd Terje Brustugun, et al.
Published: (2025-07-01)

Acquired Hemophilia A successfully treated with rituximab
by: Giovanni D'Arena, et al.
Published: (2015-02-01)

Rituximab-induced serum sickness: Not so uncommon
by: Vikramraj K Jain
Published: (2018-01-01)

Dynamics of the level of calprotectin in patients with rheumatoid arthritis during rituximab biosimilar (Acellbia “Biocad”) therapy
by: A. S. Avdeeva, et al.
Published: (2021-09-01)

The use of “Acellbia” – a biosimilar of rituximab in systemic sclerosis
by: L. P. Ananyeva, et al.
Published: (2023-08-01)

Efficacy and Safety of Subcutaneous Rituximab in Idiopathic Nephrotic Syndrome
by: Paolo Cravedi, et al.
Published: (2024-11-01)

EXPERIENCE OF RITUXIMAB TREATMENT IN A PATIENT WITH JUVENILE SCLERODERMA
by: E. I. Alexeeva, et al.
Published: (2012-05-01)

Effectiveness of rituximab in nephrotic syndrome treatment
by: Katarzyna Popko, et al.
Published: (2017-10-01)

Successful implementation of rituximab in patients with severe refractory forms granulomatosis with poliangiitis
by: Bolpačić Jasna, et al.
Published: (2018-01-01)

Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis
by: Tülay Şimşek, et al.
Published: (2017-01-01)

Rituximab Therapy for Refractory Autoimmune Thrombocytopenia in Systemic Lupus Erythematosus
by: Didem Atay, et al.
Published: (2012-03-01)

The Incidence of Electrocardiogram Changes Following Rituximab Infusion in Rheumatic Patients
by: Faraneh Farsad, et al.
Published: (2025-03-01)

Patient Monitoring during Treatment with Ocrelizumab and Rituximab (ORP-49)
by: Nazanin Razazian
Published: (2023-01-01)

Rituximab induced lung injury
by: Rohit Chari, et al.
Published: (2025-07-01)

Safety and tolerability of rituximab in the treatment of systemic sclerosis
by: L. A. Garzanova, et al.
Published: (2023-04-01)

Effect of rituximab on heart involvement in systemic sclerosis
by: L. A. Garzanova, et al.
Published: (2019-01-01)

Correlation of the Complement Decay Accelerating Factor, Tumour Necrosis Factors-alpha, and Interleukin-1 Beta with the Response to Rituximab in Rheumatoid Arthritis Patients
by: Haidar Mohammed Hussein, et al.
Published: (2025-02-01)

Safety of rituximab in the routine treatment of rheumatoid arthritis in Italy in patients refractory to anti-TNFa drugs: results from the observational retrospective-prospective RUBINO study
by: L. Bazzichi, et al.
Published: (2014-11-01)

Real-life effectiveness of rituximab in different subsets of idiopathic inflammatory myopathies
by: Stefano Stano, et al.
Published: (2025-04-01)

Rituximab como tratamiento de pénfigo refractario en pacientes mexicanos
by: Samantha Cruz-Meza, et al.
Published: (2021-06-01)

Pénfigo vulgar grave: reporte de caso de tratamiento exitoso con plasmaféresis y rituximab
by: Claudia Marcela Gaviria, et al.
Published: (2019-08-01)

Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy
by: Marco Allinovi, et al.
Published: (2025-08-01)

The Impact of Rituximab Therapy on the Chromosomes of Patients with Rheumatoid Arthritis
by: Šekib Sokolović, et al.
Published: (2010-05-01)